TKM-Ebola Overview

Reviewed: October 19, 2014

TKM-Ebola is an experimental drug to target the Ebola virus. TKM-Ebola is being developed by Tekmira Pharmaceuticals Corporation.

In January 2014, Tekmira commenced a Phase I clinical trial evaluating TKM-Ebola in healthy volunteers to test the safety and how well the drug is tolerated.

In March 2014, The Food and Drug Administration (FDA) granted Tekmira Pharmaceuticals Corporation Fast Track for the development of TKM-Ebola. The FDA's Fast Track is a process to help the development and expedite the review of drugs in order to get important new therapies to patients earlier.

Although it has not been approved, some patients have received experimental drugs, including TKM-Ebola, in hopes that it may help work against Ebola.


Patient Ratings for

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

TKM-Ebola Drug Class

TKM-Ebola is part of the drug class: